14 citations
,
July 2012 in “Journal of the American Academy of Dermatology” Topical tacalcitol ointment can help improve symptoms of EFFC.
June 2022 in “Pakistan Journal of Medical and Health Sciences” Topical clobetasol propionate 0.05% ointment is more effective in promoting hair regrowth in patients with alopecia areata than topical tacrolimus 0.1% ointment.
August 2018 in “Journal of the American Academy of Dermatology” Tofacitinib is a potential alternative treatment for alopecia totalis, especially in patients with a shorter duration of the condition and more preserved hair follicles, but the overall response rate is low.
November 2023 in “Pakistan Journal of Health Sciences” Clobetasol propionate 0.05% is more effective for hair re-growth in alopecia areata than tacrolimus 0.1%.
July 2025 in “Clinical Medicine” Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
New acne treatments like clascoterone and minocycline foam are effective, and using antibiotics carefully is important to avoid resistance.
75 citations
,
September 1971 in “British Journal of Dermatology” Both steroids effectively promote hair growth for at least 9 months.
April 2023 in “Journal of the American Academy of Dermatology” Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.
5 citations
,
August 2018 in “PubMed” An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.
10 citations
,
April 2023 in “JAAD Case Reports” The document discussed the use of topical clascoterone for treating hidradenitis suppurativa (HS), a chronic inflammatory skin disease affecting hair follicles. HS caused painful nodules, abscesses, and other symptoms, significantly impacting patients' quality of life. Despite a prevalence of up to 4%, the only FDA-approved treatment at the time was adalimumab, a tumor necrosis factor-α inhibitor. The study explored clascoterone as a potential alternative treatment option for HS.
9 citations
,
May 2021 in “International Journal of Dermatology” The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
November 2020 in “Universal Journal of Pharmaceutical Research” Tacrolimus is a better option than cyclosporine due to fewer side effects.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
1 citations
,
September 2022 in “International Journal of Trichology” Tofacitinib can be effective in treating hair loss caused by alopecia areata.
9 citations
,
November 2022 in “Journal of Cosmetic Dermatology” Combining cryotherapy with steroids reduces keloid size more effectively than steroids alone.
1 citations
,
November 2016 in “Journal of dermatological treatment” Oral tacrolimus may be a potential treatment for hair loss that doesn't respond to corticosteroids.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.
May 2017 in “Journal of The American Academy of Dermatology” An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.
January 2015 in “Journal of evolution of medical and dental sciences” Topical tacrolimus is effective and safe for treating alopecia areata.
1 citations
,
January 2021 in “Journal of clinical and diagnostic research” Using Calcipotriol with Clobetasol is more effective for treating Alopecia Areata than using Clobetasol alone.
August 2025 in “Skin Appendage Disorders” TCM is an effective and safe treatment for primary cicatricial alopecias.
49 citations
,
November 2013 in “JAMA dermatology” Clobetasol propionate, 0.05%, is more effective and safe for treating childhood alopecia areata than hydrocortisone, 1%.
September 2025 in “Tạp chí Da liễu học Việt Nam” 2.5 mg/mL TAC is as effective and safe as 5 mg/mL, but 5 mg/mL may improve hair regrowth and density more.
26 citations
,
March 2015 in “American journal of clinical dermatology” Topical clobetasol is recommended over mycophenolate mofetil for treating Lichen Planopilaris due to better safety and patient satisfaction.
January 2016 in “The Australian Pharmacist” Tofacitinib might be used to treat hair loss.
July 2025 in “Journal of the Pakistan Medical Association” Combining TCA with 5-FU is more effective and safer for treating keloids than TCA alone.